Shares of weight loss stocks are trading lower, possibly on continued weakness following recent weight loss data from Roche, which could cause competition concerns for companies in the space.

7/18/24 11:20:16 AM ET

$GPCR

$LLY

$NVO

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $GPCR alert in real time by email

Shares of weight loss stocks are trading lower, possibly on continued weakness following recent weight loss data from Roche, which could cause competition concerns for companies in the space.

Get the next $GPCR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GPCR
$LLY
$NVO

Company	Date	Price Target	Rating	Analyst
Eli Lilly and Company $LLY	10/17/2024	$1100.00	Outperform	Bernstein
Structure Therapeutics Inc. $GPCR	9/23/2024	$118.00	Overweight	Morgan Stanley
Eli Lilly and Company $LLY	9/13/2024	$1060.00	Buy	Citigroup
Eli Lilly and Company $LLY	8/12/2024	$1025.00	Hold → Buy	Deutsche Bank
Novo Nordisk A/S $NVO	5/30/2024	$156.00	Buy	Goldman
Structure Therapeutics Inc. $GPCR	5/21/2024	$65.00	Overweight	JP Morgan
Novo Nordisk A/S $NVO	4/12/2024	$163.00	Outperform	BMO Capital Markets
Structure Therapeutics Inc. $GPCR	4/9/2024	$65.00	Overweight	Cantor Fitzgerald

More analyst ratings

$GPCR
$LLY
$NVO
Financials

Live finance-specific insights

Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products
Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding revenue from the olanzapine portfolio, total revenue increased 42%, and non-incretin revenue increased 17%.Q3 2024 EPS increased to $1.07 on a reported basis and $1.18 on a non-GAAP basis, both inclusive of $3.08 of acquired IPR&D charges. 2024 revenue guidance range updated to $45.4 to $46.0 billion. 2024 reported EPS guidance updated to the range of $12.05 to $12.55, and non-GAAP EPS guidance updated to the range of $13.02 to $13.52, both driven by the acquired IPR&D charges in
10/30/24 6:45:00 AM ET
$LLY
Biotechnology: Pharmaceutical Preparations
Health Care
Lilly declares fourth-quarter 2024 dividend
INDIANAPOLIS, Oct. 28, 2024 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2024 of $1.30 per share on outstanding common stock. The dividend is payable on Dec. 10, 2024, to shareholders of record at the close of business on Nov. 15, 2024. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discover
10/28/24 11:31:00 AM ET
$LLY
Biotechnology: Pharmaceutical Preparations
Health Care
Lilly confirms date and conference call for third-quarter 2024 financial results announcement
INDIANAPOLIS, Oct. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its third-quarter 2024 financial results on Oct. 30, 2024. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call. About LillyLilly is a medicine company turning science into healing t
10/16/24 10:00:00 AM ET
$LLY
Biotechnology: Pharmaceutical Preparations
Health Care

$GPCR
$LLY
$NVO
Leadership Updates

Live Leadership Updates

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a
9/24/24 8:00:00 AM ET
$ALGS
$HAE
$NVO
$PLRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer
SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced key leadership appointments to drive its next phase of development and operational success. Blai Coll, M.D., Ph.D., has been promoted to Chief Medical Officer, replacing Mark Bach, M.D., Ph.D. as part of a planned succession, effective September 18. Dr. Coll has served as Vice President of Clinical Development at Structure since 2022, leading the GSBR-1290 program, Structure's oral small molecule GLP-1 agonist that is planned to enter Phase
9/17/24 4:05:00 PM ET
$GPCR
Biotechnology: Pharmaceutical Preparations
Health Care
Lilly appoints Lucas Montarce as executive vice president and chief financial officer
INDIANAPOLIS, Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's Executive Committee, effective immediately. Since joining Lilly in 2001, Montarce has held a range of finance leadership roles, including serving as group vice president, corporate controller and chief financial officer of Lilly Research Laboratories; vice president, finance and chief financial officer of Lilly International; and vice president, finance and global chief financial officer of Elanco Health. He most recently served in the role of Lilly president and general manage
9/9/24 6:45:00 AM ET
$LLY
Biotechnology: Pharmaceutical Preparations
Health Care

$GPCR
$LLY
$NVO
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

May 31, 2024 - FDA Roundup: May 31, 2024
For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa
5/31/24 3:22:42 PM ET
$LLY
Biotechnology: Pharmaceutical Preparations
Health Care
May 7, 2024 - FDA Roundup: May 7, 2024
For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ
5/7/24 4:10:24 PM ET
$LLY
Biotechnology: Pharmaceutical Preparations
Health Care
March 8, 2024 - FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight
For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Cardiovascular disease is a gr
3/8/24 2:00:18 PM ET
$NVO
Biotechnology: Pharmaceutical Preparations
Health Care

Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium
INDIANAPOLIS, Nov. 1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that data from the Phase 3 trial (EMBER-3) for imlunestrant, an oral selective estrogen receptor degrader (SERD), will be reported for the first time in a late-breaking oral presentation at the San Antonio Breast Cancer Symposium (SABCS) taking place December 10-13 in San Antonio, TX. EMBER-3 is a study in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. The trial is evaluating imlunestrant alone or in combination with Verzenio (abemaciclib; CDK4/6 inhibitor), in patients who were pretreated with endocrine therapy, with or without a CD
11/1/24 5:30:00 PM ET
$LLY
Biotechnology: Pharmaceutical Preparations
Health Care
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024
SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced multiple upcoming posters at The Obesity Society's Annual Meeting, ObesityWeek®, taking place from November 3-6, 2024 in San Antonio, TX. Title: Novel Oral Small Molecule Dual Amylin and Calcitonin Receptor Agonists for Obesity TreatmentPoster Number: Poster 128Date/Time: Sunday, November 3, 7:30 p.m. – 8:30 p.m. CT Location: Exhibit Hall 4 Title: Drug Design Principles and Pharmacokinetics/Pharmacodynamics of GSBR-1290, a Small Molecule GLP-
10/31/24 8:30:00 AM ET
$GPCR
Biotechnology: Pharmaceutical Preparations
Health Care
Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced positive results demonstrating the anti-inflammatory potential of our anti-CD3 antibody (foralumab) in combination with semaglutide, a GLP-1 agonist marketed by Novo Nordisk (NYSE:NVO) under the brand names Ozempic and Wegovy. The data show that the combination of nasal anti-CD3 plus semaglutide improves liver homeostasis and reduces inflammation in models of diet-induced obesity (DIO
10/30/24 8:30:00 AM ET
$NVO
$TLSA
Biotechnology: Pharmaceutical Preparations
Health Care

Shares of weight loss stocks are trading lower, possibly on continued weakness following recent weight loss data from Roche, which could cause competition concerns for companies in the space.

Chat with this insight

Recent Analyst Ratings for $GPCR$LLY$NVO

$GPCR$LLY$NVO Financials

Live finance-specific insights

Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products

Lilly declares fourth-quarter 2024 dividend

Lilly confirms date and conference call for third-quarter 2024 financial results announcement

$GPCR$LLY$NVO Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Eli Lilly and Company

SEC Form SC 13G filed by Structure Therapeutics Inc.

SEC Form SC 13G/A filed by Eli Lilly and Company (Amendment)

$GPCR$LLY$NVO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Bernstein initiated coverage on Eli Lilly with a new price target

Morgan Stanley initiated coverage on Structure Therapeutics with a new price target

Citigroup resumed coverage on Eli Lilly with a new price target

$GPCR$LLY$NVO SEC Filings

SEC Form 6-K filed by Novo Nordisk A/S

SEC Form 10-Q filed by Eli Lilly and Company

Eli Lilly and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$GPCR$LLY$NVO Leadership Updates

Live Leadership Updates

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer

Lilly appoints Lucas Montarce as executive vice president and chief financial officer

$GPCR$LLY$NVO FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

May 31, 2024 - FDA Roundup: May 31, 2024

May 7, 2024 - FDA Roundup: May 7, 2024

March 8, 2024 - FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

$GPCR$LLY$NVO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP & Pres., Lilly Oncology Van Naarden Jacob gifted 4,302 shares, decreasing direct ownership by 27% to 11,845 units (SEC Form 4)

Director Sulzberger Gabrielle was granted 11 shares, increasing direct ownership by 0.50% to 2,201 units (SEC Form 4)

Director Luciano Juan R was granted 16 shares, increasing direct ownership by 0.10% to 15,825 units (SEC Form 4)

$GPCR$LLY$NVO Press Releases

Fastest customizable press release news feed in the world

Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium

Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024

Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study

$GPCR$LLY$NVO Market Insights

Live Market Insights

Novo Nordisk's Options Frenzy: What You Need to Know

Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 15 Years

Eli Lilly and Novo Nordisk shares are trading lower after competitor Viking announced the advancement of its obesity candidate.

Recent Analyst Ratings for
$GPCR
$LLY
$NVO

$GPCR
$LLY
$NVO
Financials

$GPCR
$LLY
$NVO
Large Ownership Changes

$GPCR
$LLY
$NVO
Analyst Ratings

$GPCR
$LLY
$NVO
SEC Filings

$GPCR
$LLY
$NVO
Leadership Updates

$GPCR
$LLY
$NVO
FDA approvals

$GPCR
$LLY
$NVO
Insider Trading

$GPCR
$LLY
$NVO
Press Releases

$GPCR
$LLY
$NVO
Market Insights